New Insights on Diabetic Retinopathy Treatments Ahead of World Sight Day
As World Sight Day approaches, new research highlights the urgent need for innovative treatments in diabetic retinopathy, a leading cause of blindness.
Approximately 9.6 million Americans were affected by diabetic retinopathy in 2021.
Current treatment practices often delay intervention until vision complications arise.
Innovative therapies, including gene therapy and sustained-release options, show promise for better disease management.
With World Sight Day on the horizon, attention is drawn to diabetic retinopathy (DR), a condition that stands as the primary cause of blindness among adults of working age. In 2021, around 9.6 million individuals in the United States were diagnosed with this disease, with 1.84 million facing vision-threatening complications. The prevalence of diabetes has surged past 37 million, and the average control of blood sugar levels has deteriorated, leading to a significant increase in DR cases since 2004.
Despite the alarming statistics, treatment approaches remain conservative. A recent survey involving 103 retinal specialists and general ophthalmologists revealed that only about half of the patients receive intravitreal therapy. Many practitioners initiate treatment reactively, often only when complications arise, leaving a substantial number of patients with mild-to-moderate non-proliferative DR untreated. This demographic represents a significant market opportunity for new therapies while also highlighting a clinical gap in care.
The current treatment landscape is heavily influenced by access barriers rather than clinical preferences. Many physicians reported that insurance requirements and prior authorization processes hinder the selection of more effective biologics. As a result, Bevacizumab (Avastin), despite its lower efficacy perception, continues to dominate prescriptions due to cost considerations. In contrast, high-dose aflibercept (Eylea HD) is preferred by many physicians when unrestricted by payer constraints, thanks to its durability and higher satisfaction ratings.
Innovative treatments are emerging that aim to change the paradigm of diabetic retinopathy management. A notable advancement is Sura-vec (ABBV-RGX-314), a gene therapy that offers sustained anti-VEGF expression through a single injection. Additionally, Axpaxli (OTX-TKI) is designed for annual dosing, while Kodiak Sciences' tarcocimab tedromer proposes a dosing frequency of every six months. These developments reflect a shift towards therapies that promise longer-lasting effects and reduced treatment burdens.
As the field evolves, the integration of artificial intelligence in early detection is also gaining traction. Systems like LumineticsCore and EyeArt are now FDA-approved to identify significant disease from fundus images without needing a clinician's interpretation. These innovations could facilitate earlier interventions, addressing the critical need for timely treatment. However, for these advancements to be effective, manufacturers must ensure that new therapies are accessible and demonstrate clear improvements over existing treatments, paving the way for a future where diabetic retinopathy can be managed more effectively and preventively.
